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Abstract The discovery that a hexanucleotide repeat expan-
sion in C9orf72 is the most numerous genetic variant of both
amyotrophic lateral sclerosis and frontotemporal dementia has
opened a rapidly growing field, which may provide long
hoped for advances in the understanding and treatment of
these devastating diseases. In this review we describe the var-
ious phenotypes, clinical and pathological, associated with
expansion of C9orf72, which go beyond amyotrophic lateral
sclerosis and frontotemporal dementia to include neurodegen-
erationmore broadly. Next we take a step back and summarize
the current understanding of the C9orf72 expansion and its
protein products at a molecular level. Three mechanisms are
prominent: toxicity mediated directly by RNA transcribed
from the repeat; toxicity mediated by dipeptide repeat proteins
translated from the repeat sequence; and haploinsufficiency
resulting from reduced transcription of the C9orf72 exonic
sequence. A series of exciting advances have recently de-
scribed how dipeptide repeat proteins might interfere with
the normal role of the nucleolus in maturation of RNA binding
proteins and in production of ribosomes. Importantly, these
mechanisms are unlikely to be mutually exclusive. We draw
attention to the fact that clinical and pathological similarities
to other genetic variants without a repeat expansion must not
be overlooked in ascribing a pathogenic mechanism to
C9orf72-disease. Finally, with a view to impact on patient
care, we discuss current practice with respect to genetic
screening in patients with and without a family history of
disease, and the most promising developments towards thera-
py that have been reported to date.
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Amyotrophic lateral sclerosis (ALS) is a progressive neurode-
generative disease caused by the loss of upper motor neurons
in the motor cortex and lower motor neurons in the brainstem
and spinal cord. The majority of cases are sporadic (SALS)
but 5–10 % are familial (FALS), usually with autosomal dom-
inant inheritance. In 1993, the first pathogenic genetic muta-
tions were identified affecting Cu–Zn superoxide dismutase 1
(SOD1); SOD1 mutations account for between 12 % and
24 % of FALS cases, depending on the population sampled
[1]. There are now mutations in>20 genes identified as caus-
ative in ALS [2], of which the most common are mutations in
SOD1, the RNA binding protein encoding genes TARDBP
and FUS, and the recently identified C9orf72. Repeat expan-
sions of C9orf72 have also been associated with neurodegen-
eration elsewhere in the central nervous system (CNS), within
and outside of the motor system, as will be explored below.
Identification of the C9orf72 Repeat Expansion
The C9orf72 GGGGCC expansion was identified through
study of a risk haplotype at the 9p21 locus. Several investiga-
tions had identified the locus through linkage analysis in both
FALS and SALS, as well as FALS associated with
frontotemporal dementia (ALS-FTD) [3–8]. The delay of>
5 years between discovery of the locus and identification of
the responsible mutation is largely owing to the fact that the
expansion is intronic and has 100 % GC content, which made
it difficult to detect by traditional sequencing techniques. Ex-
pansions of>30 repeats were eventually linked to the disease
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using sequencing based on repeat-primed polymerase chain
reaction (PCR) [9, 10]. Association of the C9orf72 with the
same risk haplotype in various populations has led to the pro-
posal that a common founder is responsible for all of cases
identified [11], but this is controversial [12–15]. As C9orf72
disease has a late age of onset the mutation is not subject to
reproductive pressure, which helps explain how such a dev-
astating mutation could have become so widespread.
Observations of population frequencies of the expansion
are consistent with a common founder effect. In Finland
C9orf72 expansions were found in 61 % of patients with
FALS and 19 % of patients with SALS [11]; however, further
away from Scandinavia the expansion frequency becomes
less. In northern England C9orf72 expansions are present in
43 % of patients with ALS with an identifiable family history
and in 7 % of apparently sporadic cases [16]. In Germany
22 % of patients with FALS carry the expansion [11], but in
Japan the equivalent figure is only 3.4 % [17]. In North Amer-
ica the frequency of the C9orf72 expansion appears to be
comparable with European populations: it is reported that
36 % of patients with FALS and 6 % of patients with SALS
carry the expansion [11]. As might be expected, there is some
variability depending on ethnic group, for example no Native
Americans were identified with the expansion, but the num-
bers screened were small.
It is possible that it is not the expansion itself that is
inherited but a propensity for the region to expand. One of
the initial studies of C9orf72 noted that the risk haplotype was
associated with an increased number of repeats, even in con-
trols [10]. More recently, it has been shown that a 9p21 hap-
lotype is significantly associated with SALS, even if patients
with the GGGGCC repeat expansion are excluded [18]; per-
haps an alternative, as yet unidentified, repeat sequence is
present at the same locus.
Clinical Phenotypes Associated with the C9orf72
Expansion in ALS
The majority of non-C9orf72ALS cases are limb onset, while
25 % of patients present with bulbar onset and only 3 % with
respiratory onset [19]. Mean survival is 32 months from
symptom onset, although 14–24 % of patients have a disease
duration of>5 years and 4 %>10 years [20]. Generally, there
is no overt cognitive dysfunction at disease onset, but as the
disease progresses cognitive impairment can develop in up to
50 %, with clinically defined FTD occurring in 13–14 % of
cases [21, 22].
In C9orf72 ALS, while the full spectrum of the ALS clin-
ical phenotypes described above is represented, the most sig-
nificant and robust clinical feature associated with patients
carrying a repeat expansion is the increased incidence of
FTD or a family history of FTD in up to 50 % of cases [16,
23–27]. This is not surprising given that the 9p21 locus was
initially identified through mapping ALS-FTD families,
where cases presented with either ALS or FTD, or both dis-
eases [28, 29]. There is also an increase in the incidence of
bulbar onset in C9orf72ALS of up to 44 % compared with an
average of 25–26 % in non-C9orf72 ALS [16, 24, 26], and
several groups also found evidence of an earlier age of onset
by 1.8–5.0 years [23, 25, 27, 30]. C9orf72 ALS has also
been associated with a shorter disease duration by 5.7–
12.0 months, suggesting a more aggressive disease course
[16, 23, 25, 27].
While not all clinical cohorts show all of these characteris-
tics, the inconsistencies may not only be owing to the different
populations under consideration, but also to the groups under
comparison, as some reports compare C9orf72 ALS with all
non-C9orf72 ALS cases, whereas others compare C9orf72
ALS specifically with familial or sporadic non-C9orf72
ALS. This is highlighted in a Belgian cohort of patients with
ALS, where comparing familial C9orf72 carriers with non-
C9orf72 FALS cases showed a significant increase in the fre-
quency of bulbar onset, an increase in the age of onset, an
increase in cases with a history of FTD, and a reduction in
survival in C9orf72 ALS [31]. However, the clinical pheno-
type of sporadic C9orf72 ALS cases was not significantly
different from that of non-C9orf72 SALS. Similarly,
Millecamps et al. [32] compared the clinical phenotype of
C9orf72 ALS with that of known SOD1, TAR DNA binding
protein 43 (TDP-43) and fused in sarcoma (FUS)-related ALS
patients. Again, bulbar onset was found more frequently in
C9orf72 ALS than in the other 3 genetic variants. While
C9orf72 ALS cases had shorter disease duration compared
with SOD1 and TDP-43-related ALS cases, and an older age
of onset compared with SOD1 and FUS-related ALS, the con-
sistent finding in this analysis was the increased incidence of
FTD or a family history of dementia identified in the patients
withC9orf72ALS. In families where ALS-FTD is the clinical
phenotype, mutation screening has shown that the C9orf72
expansion accounts for around≥50 % of the cases [33–37].
Finally, given the variability in C9orf72 disease, it is likely
that there are a significant number of genetic and environmen-
tal modifiers; a number of candidates, including the length of
the repeat expansion, will be discussed below.
ALS and Parkinson’s Disease/Parkinsonism
During the screening of C9orf72 in ALS cohorts, it was noted
that there was also an apparent increase in the incidence of
Parkinson’s disease (PD), parkinsonism concomitant with
ALS or a family history of PD [16, 33]. However, screening
for the C9orf72 expansion in cohorts of PD cases identified a
few rare incidences of the repeat expansion, usually in cases
with atypical Parkinson’s disease [38–40]. Given the high
incidence of ALS and parkinsonism-dementia-complex in
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the Kii peninsula of Japan and in the Chamorro inhabitants of
Guam, individuals were screened to see if the C9orf72 expan-
sion contributed to this pathology. Whereas no C9orf72 ex-
pansions were found in the Charmorro population [41], 3
(20 %) ALS cases carried an expansion in the Kii Peninsula,
a frequency significantly higher than across the rest of Japan,
suggesting C9orf72 expansions do contribute to the preva-
lence of ALS in this high incidence geographical focus [42].
Further reports failed to find C9orf72 expansions over 30
repeats in PD in the Chinese Han and US white populations
[43, 44]. However, both disease cohorts showed an increase in
the number of intermediate repeats compared with controls. In
the American population 14 cases had 20–30 repeats (com-
pared with 3 controls), while 7 cases had>23 repeats [44]. In
the Chinese population, 3 PD cases had repeat lengths of 20–
30 (compared with zero controls) and>7 repeats was found to
be significantly associated with PD [43].
Spectrum of C9orf72-associated Diseases
As well as ALS, C9orf72 GGGGCC repeat expansions are
commonly found in FTD, and the spectrum of C9orf72 dis-
eases extends from both ALS and FTD to other motor disor-
ders such as primary lateral sclerosis (PLS), progressive mus-
cular atrophy (PMA), and Huntington’s disease (HD)
phenocopies, as well as other non-motor disorders, such as
Alzheimer’s disease (AD).
Motor Disorders Associated with C9orf72 Repeat Expansions
While ALS is characterized by the degeneration of both the
upper and lower motor neurons, PLS is caused by the loss of
upper motor neurons and PMA by the loss of lower motor
neurons. These are predominantly sporadic disorders. How-
ever, screening of C9orf72 has found repeat expansions to be
present within these disease phenotypes, in 0.9–8.7 % of PLS
cases and 1.6–25.0 % of PMA cases from Dutch, Canadian,
and Spanish populations [24, 27, 30]. In contrast, no expan-
sions were seen in PLS and PMA cohorts from Germany and
the USA [37, 45]. They were also absent from cohorts of
spinal muscular atrophy and patients with hereditary spastic
paraplegia [45–47].
C9orf72 has also been screened for in HD-like syndromes,
where repeat expansions were found in 7 cases, at a frequency
of 1.7 %, which was significantly more frequent than the
presence of expansions in controls (0.15 %) [14]. Subsequent-
ly, in a large cohort of 514 HD phenocopies, expansions were
identified in 10 cases (1.95 %), thereby establishing C9orf72
repeat expansions as the most commonly identified genetic
cause of a HD mimic syndrome [48]. In this study, HD
phenocopies were identified by the presence of a clinical triad
of psychiatric, movement, and cognitive impairment in the
absence of a CAG repeat expansion of huntingtin. In all cases
diagnosis was made by an experienced clinician, although, of
course, when classification is purely clinical there remains the
possibility that some of these cases may have been wrongly
selected.
Rare cases of corticobasal syndrome have been reported as
having a C9orf72 expansion [39, 40], as has a case of progres-
sive supranuclear palsy [39]. In a cohort of 209 cases of
spinocerebellar ataxia, an expansion was found in a single
patient, whose father also carried the repeat and had ALS
[49]. In addition, a brother and sister, both of whom were
carrying a C9orf72 expansion, presented with ALS and mul-
tiple system atrophy, respectively [50]. Finally, a C9orf72 ex-
pansion was also found in a Finnish patient who developed a
dysplastic gangliocytoma usually associated with mutations in
PTEN. This individual also exhibited the characteristic pathol-
ogy associated with C9orf72 expansions (see ‘Neuropatholo-
gy ofC9orf72Repeat Expansions’).Whether or not these later
examples are rare coincidences, or specifically related to the
C9orf72 expansion, remains to be determined. However, it is
clear from the PMA, PLS, and HD phenocopies that the
C9orf72 phenotype extends beyond the classical motor disor-
der of ALS.
Non-motor Disorders with C9orf72 Repeat Expansions
Following identification of the GGGGCC repeat expansion in
C9orf72 in ALS-FTD, screening of FTD cases found the re-
peat expansion accounted for 25.1 % of familial FTD and
5.8 % of sporadic cases worldwide, although, as with ALS,
the frequency does vary within different populations [11].
While FTD can present as behavioral variant FTD (bvFTD),
progressive nonfluent aphasia, or semantic dementia, those
with the C9orf72 expansion predominantly present with
bvFTD, including progressive personality deterioration, such
that affected individuals may exhibit psychosis in the form of
hallucinations and delusions [11]. The frequency of bvFTD is
consistently higher in patients with C9orf72 FTD than in non-
C9orf72 FTD cases in multiple populations across the world
[13, 36, 51, 52]. Some patients with C9orf72 expansions do
present with PNFA with loss of word retrieval and nonfluent
speech culminating in loss of speech, but the frequency of this
presentation was similar in both C9orf72 and non-C9orf72
cohorts [36]. In contrast, semantic dementia, where individ-
uals lose their understanding of words and objects, is only
rarely associated with C9orf72 expansion [51, 53].
As C9orf72 repeat expansions are associated with demen-
tia, cases with AD were screened to determine whether the
GGGGCC repeat also contributed to AD. Some cohorts do
contain C9orf72 expansions at relatively low frequencies
(0.76 %), but this includes cases with pathologically con-
firmed AD [54–56]. However, other reports have failed to
identify any expansions with>30 repeats in AD cases [52,
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57, 58]. In addition,owing to the prevalence of psychosis
symptoms associated with C9orf72 FTD, cohorts of schizo-
phrenia patients have also been screened for the expansion
[59, 60]. However, only 1 report has identified repeats>30
in 2 of 298 (0.67 %) patients with schizophrenia [61]. Simi-
larly, only 1 individual with bipolar disorder has been found
with a C9orf72 repeat expansion, although the affected parent
who passed on the repeat and was originally diagnosed with
bipolar disorder went on to also develop FTD [62]. It remains
to be established if these mutations are truly causative in these
non-motor system disorders or if the associations are due to
chance, as C9orf72 expansions are seen in 0.15 % of UK
controls [14], and the expansion has been reported to show
incomplete penetrance in an Italian cohort [63].
Neuropathology of C9orf72-related ALS
The C9orf72 expansion is associated with classical Bunina
bodies (Fig. 1), and p62 and TDP-43-positive neuronal cyto-
plasmic inclusion (NCI) and glial cytoplasmic inclusion
pathology in the motor cortex and anterior horns of the spinal
cord, and with marked loss of motor neurons [16]. Thus,
C9orf72-related ALS is a TDP-43 proteinopathy, similar to
most other subtypes of ALS. However, the repeat expansion
cases have additional characteristic pathology in the cerebel-
lum and hippocampus. p62 and ubiquitin-positive but phos-
phorylated TDP-43-negative NCI have been identified in the 3
layers of the cerebellar cortex, the hippocampus (especially
the pyramidal cells), and the neocortex [16, 24, 64]
(Fig. 1c). In addition, neuronal intranuclear inclusions were
found in the cerebellar granular cells and hippocampal pyra-
midal cells [65]. The pathology in these extramotor regions,
which were not thought to be affected in ALS, were first
described in FTD and FTD-ALS [66, 67], and subsequently
in ALS [68], before being associated with the C9orf72 expan-
sion [65].
The NCIs and neuronal intranuclear inclusions, as well as
being positive for ubiquitin and p62, also stain for dipeptide
repeat proteins (DPRs) (Fig. 1d), which are thought to be
generated through repeat-associated non-ATG translation
(RAN; see BProtein Toxicity^) [69]. The sense DPRs (poly-
Fig. 1 Characteristic pathology
of C9orf72 amyotrophic lateral
sclerosis (ALS).Motor neurons of
the spinal cord display typical
TAR DNA binding protein-43
(TDP-43) pathology, including
cytoplasmic TDP-43 positive
skeins and compact inclusions
[(A), anterior horn, stained with
3,3' diaminobenzidine (DAB) for
pTDP-43, scale bar 100 μm] and
Bunina bodies [(B), anterior horn,
hematoxylin and eosin stain, scale
bar 100 μm]. However, in addi-
tion, patients with C9orf72 ALS
display p62-positive cytoplasmic
inclusions in extramotor areas
[(C), hippocampus dentate gyrus,
DAB stained for p62, scale bar
100 μm], which also stain for
dipeptide repeat protein [(D),
cerebellar granule neurons,
stained for poly-GA and 4',6'-
diamidino-2-phenylindole
(DAPI), scale bar 3 μm].
Numerous tissues also show
nuclear RNA foci [(E), cerebellar
granule neurons, stained for
(GGGGCC)3 and DAPI, foci are
indicated by arrowheads, scale
bar 3 μm]
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GA, poly-GR, and poly-GP) generally co-localize with the
p62-positive NCI in the cerebellum and hippocampus. DPRs
are also generated from antisense transcripts, although these
appear to stain less than the sense DPRs in postmortem mate-
rial [69–71]. Both sense and antisense DPRs have been iden-
tified in motor areas, including spinal motor neurons [71].
However, the relative frequencies of the DPR species in var-
ious neuronal populations remains to be definitively deter-
mined. Study of C9orf72 neuropathology has led to a sugges-
tion as to why parkinsonism is more commonly seen in
C9orf72 ALS cases. An increased number of p62-positive
and TDP-43-negative NCIs have been found in the substantia
nigra of C9orf72-related ALS cases, and this is associated
with a marked loss of dopaminergic neurons [38].
Finally, all tissues thus far examined in patients carrying
C9orf72 expansions contain nuclear RNA foci transcribed
directly from the C9orf72 expansion in both a sense and an
antisense direction (see BRNAToxicity^) (Fig. 1e) [72–74].
Function of the C9orf72 Protein
Little is known about the normal role of the C9orf72 protein.
The most conserved residues in C9orf72 are distributed
throughout the protein, suggesting that it functions as a single
block [75]. The use of 6 independent structure prediction tools
to examine the primary sequence of C9orf72 suggested a
number of possible functional domains, including a BM16
peptidase^, a Bcytochrome bcl^, a Bglycohydrolase^, and a
Bdifferentially expressed in normal and neoplasia^ (DENN)
domain [75]. Interestingly, a DENN domain was predicted by
5 of the 6 tools; DENN proteins are Rab-guanosine
triphosphate/guanosine diphosphate exchange factors. More-
over, examination of the predicted secondary structure of
C9orf72 also revealed significant homology with DENN pro-
teins [75]. This has led to the suggestion that C9orf72 is im-
portant in the regulation of Rab activity and thus membrane
trafficking, a proposal supported by another study showing
that the C9orf72 protein co-localizes in neurons with Rab
proteins and membrane vesicles implicated in autophagy and
endocytosis [76]. This study also suggested that mutant
C9orf72 had an enhanced interaction with Rab7 and Rab11
compared with controls, suggesting that the role of C9orf72 in
membrane trafficking may be perturbed in C9orf72 disease
[76]. Alsin, another protein associated with early-onset ALS,
is also thought to be a DENN protein with a role in membrane
trafficking [77]. One note of caution in interpreting the report
of Farg et al. [76] is that a widely accepted C9orf72 antibody
with optimal sensitivity and specificity has yet to emerge.
An alternative approach, which is not dependent on an
antibody, is to determine locations where the C9orf72 gene
is expressed. Transcription of the mouse C9orf72 ortholog is
enriched in neuronal populations vulnerable to ALS/FTD
[78]. This is in direct contrast to other proteins implicated in
genetic variants of ALS, including TDP-43 and SOD1, which
are ubiquitously expressed. If haploinsufficiency is crucial to
the pathophysiology of C9orf72 disease, then understanding
the role of the C9orf72 proteins in these neurons is likely to be
key, whereas if gain-of-toxicity is the mechanism then vulner-
able populations may be selected by C9orf72 expression.
As well as studying C9orf72 protein function directly,
study of modifiers of C9orf72-disease has the potential to
illuminate detail about the normal and the pathological role
of the protein. A genome-wide association study identified
single nucleotide polymorphisms in TMEM106B as a risk
factor for FTD with TDP-43 positive pathology (which in-
cludes C9orf72-related FTD) [79]. The protein product of
TMEM106B is localized to the lysosome. The haplotype as-
sociated with higher risk of FTD-TDP, more particularly the
major, or T, allele of rs1990622, has recently been investigated
in the context of C9orf72 disease [80]. The major allele is
present at a higher than control frequency in patients with
C9orf72 FTD and is associated with an earlier age of onset
inGRN-related FTD. However, in patients withC9orf72 FTD,
the major allele is associated with a later age of onset and
death. This fascinating complexity suggests that both proteins
have similar functions and, notably, that membrane trafficking
is a component of lysosome function. It has been suggested
that the protective isoform of TMEM106B is expressed at a
lower level because of increased degradation mediated via
altered glycosylation [81]. Interestingly, in contrast to the
C9orf72 FTD findings, it has been shown that neither
TMEM106B allele is significantly associated with a
C9orf72-related ALS presentation [82]. Why the
TMEM106B genotype modifies the risk of 1 phenotype and
not the other is unknown, but this suggests that the mechanism
of neurotoxicity may be different in each case.
Another study aiming to identify genetic modifiers of
C9orf72 disease studied genetic risk factors already associated
with ALS in C9orf72- expansion carriers and controls. These
included altered copy number of survival of motor neuron
1 (SMN1) and survival of motor neuron 2 (SMN2), CAG re-
peat expansion of ataxin 2 (ATXN2) and GCG repeat expan-
sion of nonimprinted in Prader-Willi/Angelman syndrome
1 (NIPA1) [83]. Only ATXN2 expansions of>27 units were
present at a higher rate in the C9orf72 expansion carriers,
mirroring the findings in ALS more generally [84]. When this
result was broken down by phenotype, it was striking that
intermediate-length ATXN2 expansions were present in 2–
3 % of patients with ALS or ALS/FTD but were absent in
75 patients with FTD, suggesting that expansion of ATXN2
may predispose C9orf72 expansion carriers to develop ALS
or ALS/FTD rather than pure FTD. A recent study has con-
firmed these findings in a larger cohort of patients with ALS,
ALS/FTD, and FTD. More than 28 unit expansions of ATXN2
were present at a higher frequency than in controls in both
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patients with ALS and ALS/FTD but not patients with pure
FTD, and this was true in groups with and without C9orf72
expansions [85]. It has been suggested that polyglutamine
(polyQ) expansion of ATXN2 increases the stability of the
protein, enhances its interaction with TDP-43, and may pro-
mote cytoplasmic mislocalization of TDP-43 [84]. TDP-43 pa-
thology is a feature of both ALS and FTD, and it remains to be
discovered why expansions of ATXN2 predispose to ALS and
not FTD. The fact that this effect appears to be present inde-
pendently of C9orf72 expansion suggests that ATXN2 may
have an impact on the Bfinal common pathway^ of disease.
Pathogenic Mechanism(s) of the C9orf72 Repeat
Expansion
The mechanism of neurotoxicity in C9orf72 disease is un-
known. However, evidence is being gathered for 3 potential
mechanisms, all of which have precedence in other neurolog-
ical diseases mediated by repeat expansions: 1) RNA-based
toxicity of the transcribed repeat; 2) protein-based toxicity via
translation of the expanded RNA to form DPRs; and 3)
haploinsufficiency.
RNAToxicity
RNA foci formed from the repeat sequence were observed in
the earliest studies of C9orf72 disease [9]. The numbers of
RNA foci have been correlated with pathogenic severity in
cell models [86, 87], and in tissue from FTD cases [73]. A
number of molecular phenotypes have been linked to the
RNA foci [73, 74, 86–89].Most groups appear to be exploring
the idea that RNA foci sequester and therefore alter the func-
tion of certain proteins, including, for example, adenosine
deaminase, RNA-specific, B2 leading to excitotoxicity [87],
and nucleolin leading to nucleolar stress (Fig. 2) [89]. In view
of the relatively late age of onset of C9orf72 disease and the
extremely variable phenotype, we have proposed a model
whereby dynamic sequestration of a relatively large number
of RNA binding proteins might have a low-level effect on
nuclear speckle function (Fig. 2), which, in time, might pre-
cipitate disease [72]. Interestingly, we and others, have ob-
served RNA foci in tissue from presymptomatic patients with
no clinical disease [72, 73].
It is now clear that stabilized RNA foci are formed from
transcription of the GGGGCC repeat in the sense and the
antisense direction [70, 73, 74, 89]. Binding partners of the
sense and antisense RNA foci are broadly similar and are
significantly enriched for RNA-binding proteins [89]. The
relative importance of sense and antisense species to the path-
ophysiology of neuronal injury remains to be determined.
Observations of the transcribed repeat also have a bearing
on the formation of DPRs as this requires inappropriate
nuclear export to allow the RNA to access the translation
machinery. Indeed, cytoplasmic RNA foci have been ob-
served in CNS neuronal populations, including motor neu-
rons, by ourselves and others [72, 74]. In a postmitotic neuron
this could not be achieved by nuclear extrusion duringmitosis.
We have shown that sense RNA foci interact directly with
export adaptors, including Aly/REF export factor (ALYREF)
[72], and we propose that this interaction might inappropriate-
ly license the repeat RNA for export to the cytoplasm. If DPRs
are toxic, this represents an attractive therapeutic target. It is
interesting to note that pathological analysis suggests that the
coincidence in cells of sense/antisense RNA foci and DPR
inclusions is relatively low [70], which may suggest that the
formation of transcripts into foci and the cytoplasmic export of
transcripts for translation, if not mutually exclusive, are medi-
ated independently. If one of these processes is identified as
toxic and one as protective thenmodulating this decision point
may represent a therapeutic target.
It is also possible that RNA species transcribed from the
hexanucleotide repeat are toxic by some other mechanism. For
example, it has been suggested that the sense and antisense
transcripts might form inappropriate double-stranded species,
which could initiate apoptosis [90]. However, preliminary da-
ta suggest that denaturation and renaturation of the GGGGCC
repeat in the presence of its antisense complimentary sequence
produces a relatively small proportion of double-stranded
RNA, in contrast to a similar experiment using the myotonic
dystrophy associated CUG repeat [91]. This study concluded
that their observations were the result of formation of the
Fig. 2 Proposed mechanisms of toxicity mediated by protein
sequestration to RNA foci. Various proteins have been shown to be
sequestered to RNA foci transcribed either in the sense or antisense
direction from the GGGGCC repeat sequence. Proposed mechanisms
include sequestration of proteins important to mRNA splicing with
consequent disruption of RNA splicing; sequestration of adenosine
deaminase, RNA-specific, B2 (ADARB2) (nonfunctional) leading to
increased susceptibility to excitotoxicity; and sequestration of nucleolin
producing nucleolar stress
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GGGGCC repeat sequence into unimolecular stabilized G-
quadruplexes where bases are not readily available for Wat-
son–Crick pairing. Study of the secondary structure of the
transcribed repeat is in itself likely to be useful in the devel-
opment of therapies, particularly if successful therapy requires
prevention of protein binding to the RNA. More recently, 2
studies have suggested that the sense RNA exists in equilibri-
um between 2 possible confirmations: a hairpin loop and a G-
quadruplex [89, 92]. In contrast, the antisense RNA appears
not to be able to adopt a G-quadruplex conformation and to
therefore exist primarily in a hairpin loop [89]. These in vitro
findings are informative and have already led to the develop-
ment of a potential small molecule therapeutic agent (see
BTherapeutics for C9orf72 Disease^), but should be
interpreted with caution—the effect of the normal neuronal
environment is unknown.
Protein Toxicity
Precedence from other repeat expansion disorders led to the
search for and the discovery of DPRs in C9orf72 disease [93].
Antibodies were developed to 3 different proteins, poly-(Gly-
Ala), poly-(Gly-Pro), and poly-(Gly-Arg), based on the possi-
ble reading frames from which the expansion could be trans-
lated. All 3 species were identified within ubiquitinated neu-
ronal cytoplasmic inclusions in C9orf72 patients. Following
the description of antisense transcription of the repeat se-
quence 2 further proteins were identified corresponding to
the 2 additional distinct reading frames, poly-(Ala-Pro) and
poly-(Pro-Arg) [71]. Notably, all of the protein species have
been identified within ubiquitinated cytoplasmic inclusions
and in several cases were observed to co-aggregate [71].
The poly-PR and poly-GP proteins are associated with a
potential ATG start codon, but the other species must be trans-
lated via a noncanonical mechanism, which is as yet unknown
and may mediate translation of all of the proteins. It is pro-
posed that translation may be initiated directly by the repeat
expansion, as has previously been observed [94], so-called
RAN translation. In this study of spinocerebellar ataxia 8, a
neuromuscular disorder caused by a CAG repeat expansion of
the ataxin 8 gene, Zu et al. [94] showed that translation of the
repeat sequence occurred independently of the presence of an
ATG site. As with the C9orf72 expansion, translation was
demonstrated in 3 independent reading frames corresponding
to polyQ, polyserine, and polyalanine. Interestingly, the rela-
tive mix of these protein species varied depending on the
repeat length. They also concluded that the hairpin secondary
structure in the RNA is important for RAN translation as a
CAA repeat with similar properties, but without the ability to
form a hairpin secondary structure, was translated only in the
presence of an ATG start codon. This work has already had a
significant effect on the study of C9orf72 disease, and it is
likely that it will continue to do so. Work with a transfected
GGGGCC repeat sequence has demonstrated length depen-
dence of translation of the poly-PR and poly-GP proteins in
a cell model [70].
DPR appears to be toxic in cell and animal models [95–97].
However, neuropathological studies find no relationship be-
tween the extent of the DPR pathology and clinical severity
[98]. In fact, levels of the aberrantly translated protein appear
to correlate inversely with vulnerability of different neuronal
groups to neurodegeneration in autopsy material, in direct
contrast to the levels of TDP-43-positive inclusions [99]. This
may be consistent with a protective role for the formation of
DPRs. However, it should be noted that this was a study of
pathological material and at the end stage of disease it is im-
possible to rule out the possibility that the neurons that have
already died are the ones containing the highest burden of
DPRs. Time course studies in model systems will be required
to shed light on this ambiguity.
Very recently, 3 intriguing studies have moved this debate
forwards. Kwon et al. [96] have provided evidence from a cell
model that the poly-GR and poly-PR DPRs may bind irrevers-
ibly to the nucleolus, leading to toxicity via disruption of pre-
mRNA splicing and ribosome synthesis (Fig. 3) [96]. The
association SR of domains with nucleoli has been observed
previously and shown to be dependent on phosphorylation
[100]. Kwon et al. [96] have extended this finding to SR
domain-containing proteins implicated in ALS. Moreover,
they suggest that the poly-GR and poly-PR proteins associate
Fig. 3 Proposed mechanisms of toxicity mediated via translation of
dipeptide repeat protein (DPR). Both sense and antisense, or GGGGCC
and GGCCCC repeat RNA species are observed to be translated into
DPRs. The absence of traditional ATG start sites has led to the proposal
that this occurs via a repeat-associated initial or repeat-associated non-
ATG (RAN) translation. The various DPR sequences are proposed to be
toxic via a number of mechanisms, including disruption of normal pro-
cessing of RNA-binding proteins associated with the nucleolus leading to
nucleolar stress and/or disruption of normal RNA splicing; or disruption
of normal protein processing pathways leading to formation of protein
inclusions and toxic protein stress. Implicated DPR species are shown for
each mechanism
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irreversibly with the nucleolus because, unlike SR domains,
they lack serine residues and are therefore unable to undergo
phosphorylation by CLK1/2 protein kinases. The nucleolar
target of arginine-rich domains is unknown, but the authors
speculate that the irreversible binding of DPRs might disrupt
the normal processing, and therefore the function, of SR pro-
teins in pre-mRNA splicing, and might also disrupt the normal
function of the nucleolus in the synthesis of ribosomal RNA.
As evidence in support of this hypothesis, they demonstrate
changes in the splicing of the excitatory amino acid transport-
er-2 (EAAT2) and in the production of small nucleolar RNA
upon administration of PR20. Although narrow, these changes
are reminiscent of molecular phenotypes reported previously
in ALS [101]. Intriguingly, this offers an alternativemechanism
for the nucleolar stress observed by Haeusler et al. [89] de-
scribed above. This interesting set of observations awaits con-
firmation and further development. In particular, the effect of
dipeptide repeat length is unknown and a direct link to the
disease remains to be established. PR20 could be generated from
a GGGGCC expansion of 20 units, which is within the range
found in controls, although the use of supraphysiological levels
in the study may have effectively simulated the presence of a
larger expansion.
This proposed model was strengthened shortly after by the
work of Mizielinska et al. [97], who demonstrated neurode-
generation in aDrosophilamodel upon expression of poly-GP
and poly-PR proteins. Toxicity was not present on expres-
sion of poly-PA protein and was relatively minor upon
expression of poly-GA protein [97]. Importantly, this
study included an BRNA-only^ model by expression of
stop codon-interrupted GGGGCC repeats, which pro-
duced RNA foci but not DPRs. The BRNA-only^ model
formed RNA foci but was not toxic at any repeat length
tested (up to 288 repeats). The authors note that the repeat
lengths tested are much shorter than expansion lengths
present in patients with C9orf72 disease and therefore this
result does not exclude RNA toxicity. They did not de-
scribe any length dependence of the DPR toxicity, but
they did show amelioration of toxicity by inhibition of
protein translation.
Potentially bringing these 2 studies together, May et al.
[102] examined the pattern of expression of the 5 dipeptide
species in human embryonic kidney 293 cells. The arginine-
rich peptides produced dot-like intranuclear inclusions, which
may correspond to the nucleolar sequestration proposed by
Kwon et al. [96]. May et al. [102] described a potential mech-
anism of pathogenesis associated with poly-GA repeats
(Fig. 3). They reported ubiquitination and toxicity of cytoplas-
mic poly-GA inclusions associated with interaction between
poly-GA and a number of components of the ubiquitin–pro-
teasome system, including Unc119. Unc119 co-localized with
poly-GA inclusions in brains of patients with C9orf72 FTD,
and knockdown of unc119 was neurotoxic in a cell model.
This fascinating picture is only likely to becomemore com-
plicated as understanding of the behavior of DPRs grows.
Drawing insights from the polyQ literature, a significant num-
ber of interacting partners of polyQ proteins have proven to be
genetic modifiers of the disease; as many as 45% of identified
interacting partners modified toxicity in a Drosophila model
of HD [103]. It is possible that a large number of interactions
are important, including but not confined to the nucleolus and
components of the ubiquitin–proteasome system.
Role of TDP-43
As mentioned previously, C9orf72-related ALS is a TDP-43
proteinopathy, in common with most other subtypes of ALS,
with the exception of SOD1-related ALS [104]. What is cur-
rently unclear is how the mislocalization of TDP-43 from the
nucleus to the cytoplasm in all these cases contributes tomotor
neuronal death. However, evidence suggests that the toxicity
is most likely due to dysregulation of RNA processing and
protein homeostasis, specifically impairment of the ubiquitin
proteasome system, the unfolded protein response, and au-
tophagy, rather than TDP-43 aggregates themselves being tox-
ic [105]. Interestingly, p62, which is an autophagy receptor
protein encoded by SQSTM1, not only co-localizes with TDP-
43 aggregates in the brain and spinal cord of C9orf72-related
cases, but also with the TDP-43 negative, ubiquitin-positive
inclusions, which have been observed to contain DPRs, in the
extramotor regions of the brain. Thus, dysregulated protein
homeostasis appears to be a common feature of C9orf72-re-
lated ALS and other subtypes of ALS.
Haploinsufficiency
Reduced expression of C9orf72 mRNA has been reported in
the presence of the expansion [9]. However, this finding is not
consistent [86]. Most recently, study of a newly generated
C9orf72 antibody suggests that there is reduced expression
of the C9orf72 protein in the frontal cortex, but not in the
cerebellar cortex of C9orf72 expansion carriers [106].
It has been demonstrated that small expansions of approx-
imately 50 repeats do not reduce C9orf72 transcription [107],
possibly because smaller expansions do not lead to hyperme-
thylation of a CpG island 5’ to the repeat sequence in the
promoter region [108, 109]. If smaller repeat lengths are path-
ogenic [110, 111], then haploinsufficiency is not the respon-
sible mechanism. Developing this story further, CpG hyper-
methylation of the C9orf72 promoter has been shown to cor-
relate with the burden of pathology: the presence of promoter
hypermethylation is associated with reduced accumulation of
DPRs and RNA foci in the CNS of C9orf72 patients [112].
Moreover, the same study showed in lymphoblastoid cell lines
derived from C9orf72 expansion carriers that demethylation
of the promoter led to increased vulnerability of the cells to
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oxidative and autophagic stress. While not conclusive, this
suggests that reduced expression of expanded C9orf72 might
be protective rather than pathogenic. A number of other mech-
anisms have been proposed for haploinsufficiency:
trimethylation of histones H3 and H4 has been reported in
C9orf72 expansion carriers and linked to increased binding
of these histones to the repeat sequence with consequent re-
duced expression ofC9orf72 [113]. Finally, biochemical anal-
ysis has suggested that formation of expanded C9orf72 DNA
and RNA into hybrid R loops may also contribute to abortive
transcription [89].
Friedreich’s ataxia is a neuromuscular disorder associated
with an intronic repeat expansion in the frataxin gene. In this
disease the mutation must be homozygous to be pathogenic
and haploinsufficiency has been confirmed at the protein lev-
el. Drawing parallels with C9orf72, the frataxin repeat expan-
sion has been associated with epigenetic silencing. However,
additional mechanisms have been identified: blockage of tran-
scription elongation by DNA repeat secondary structure has
been demonstrated [114], and the presence of the repeat ex-
pansion has been shown to reduce levels of mature frataxin
mRNAvia interaction with trans-acting splicing factors [115].
The latter mechanism might explain some of the controversy
in the measurement of C9orf72 mRNA as the diversity of
splice variants produced might lead to contrasting results in
various quantitative PCR assays, depending on the primers
utilized. It remains to be seen whether a similar mechanisms
are at play in C9orf72 disease.
Another observation not consistent with a pathogenic
role for haploinsufficiency comes from 2 patients with
expansions of both C9orf72 loci; 1 a homozygote and
the other a compound heterozygote [107, 116]. Both cases
suffered FTD, but neither phenotype was outside the usual
phenotypic spectrum. This is not consistent with a pure
haploinsufficiency model, which would predict disease
severity in proportion to the number of involved alleles.
It remains to be seen whether haploinsufficiency is a
disease modifier, but this evaluation may be just around
the corner if the newly developed antibodies become
widely accepted as sensitive and specific.
Repeat Length as a Modifier of C9orf72 ALS
Clearly, the first 2 of the potential pathogenic mechanisms
discussed above are gain-of-function toxicities. In a gain-of-
function scenario, it would be predicted that disease severity is
proportional to repeat length. However, a conclusive relation-
ship between repeat length and disease severity has not yet
been demonstrated. Measurement of repeat length initially
proved technically challenging as the large GC rich region is
not amenable to standard PCR-based sequencing. However,
several groups have now optimized Southern hybridization-
based techniques [14, 117, 118]. Currently, in a pure ALS
group, no aspect of the disease phenotype has been shown
to correlate significantly with the length of the expansion,
regardless of the tissue tested [118, 119]. In FTD, a direct
correlation between repeat size in the frontal cortex and age
of onset has been demonstrated, and in the cerebellum a
threshold repeat size has been associated with reduced surviv-
al [118]. This report also indicated that the repeat length in the
cerebellum was shorter than in other CNS areas. It is hypoth-
esized that repeat expansions can increase in size through a
human lifetime, resulting in significant somatic heterogeneity
[120], and, therefore, perhaps the minimum repeat length in
the CNS is more reflective of the germline repeat number. If
so, the expansion length in the cerebellum may best represent
the repeat length that initiated the disease pathogenesis, and
the correlation with age of onset in frontal cortex may simply
reflect the patient’s age.
An alternative way to approach this problem is to look for
evidence of anticipation in C9orf72-related disease, which
would be highly suggestive of a relationship between repeat
size and disease severity. A series of C9orf72-FTD and
C9orf72-ALS families have been described [26, 121], with
7–10 years of anticipation between generations.
Against a direct relationship between repeat length and
disease severity is the description of patients with significant
clinical disease but a relatively small repeat lengths of<30
units [110, 111]. Repeat lengths of 7–24 units are associated
with the 9p21 risk haplotype [122]. We have recently
Fig. 4 Proposed therapeutic approaches for C9orf72 disease. At this
point, 2 therapeutic approaches have been proposed and partially
demonstrated for C9orf72 disease. First, an antisense oligonucleotide
approach whereby the introducedmolecule forms a double-stranded com-
plement with the transcribed repeat sequence and thus targets it for deg-
radation by RNAse H. This has been reported to reverse the formation of
RNA foci and rescue certain molecular phenotypes. Second, a small
molecule approach targeting the secondary structure of GGGGCC repeat
RNA, which is thought to be in equilibrium between a hairpin and a G-
quadruplex conformation, has been shown to disrupt both formation of
RNA foci and translation of dipeptide repeat proteins (DPR)
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described a patient with clinical ALS, an intermediate expan-
sion of 16 GGGGCC repeats and the 9p21 risk haplotype, but
without the typical neuropathology associated with C9orf72
disease, including RNA foci, DPR inclusions, and TDP-43-
negative, p62-positive neuronal inclusions in extramotor areas
[123].We suggest that the pathological characterization of this
case indicates that this individual actually suffered from non-
C9orf72 ALS and the intermediate length expansion was not
sufficient to initiate typicalC9orf72-mediated neuronal injury.
Consistent with this, the frequency of 7–24 repeats, unlike that
of longer repeats, is equivalent in patients and controls [122].
That patients and controls with intermediate-length expan-
sions also tend to carry the 9p21 risk haplotype may reflect
the suggestion made earlier, that the risk haplotype predis-
poses the region to expand; however, we suggest that a min-
imum length, probably much greater than 30 repeats, is nec-
essary to initiate C9orf72-neuropathology.
Therapeutics for C9orf72 Disease
Understanding of pathogenesis related to C9orf72 repeat ex-
pansion is increasing but some attractive upstream therapeutic
targets have already arisen. If disease is initiated by RNA foci
and/or DPRs formed from the repeat sequence, then selective-
ly preventing transcription and/or translation of the repeat
might prevent toxicity. Some progress has already been made
in this and is described in detail elsewhere in this series. How-
ever, briefly antisense oligonucleotides have been utilized to
promote degradation of C9orf72 transcripts [73, 86, 87], and
more recently the use of small molecules that bind the second-
ary structure of the repeat sequence have been shown to in-
hibit formation of RNA foci and translation to form DPRs
(Fig. 4) [92].
Genetic Screening of C9orf72 in ALS
The discovery of C9orf72 hexanucleotide repeat expansions
as a cause of ALS is hugely important, not least because this
genetic subgroup represents such a substantial proportion of
patients with ALS. C9orf72 expansions account for approxi-
mately 10–20 % of total ALS cases in different populations,
including a proportion of cases with apparently sporadic dis-
ease. This frequency means that, for the first time, there is the
opportunity to study preclinical through to clinical disease
systematically, and also to evaluate a specific molecular sub-
group separately when testing new potential neuroprotective
agents in clinical trials.
Clinical genetic screening for C9orf72 expansions can be
reliably undertaken by the use of a combination of amplicon-
length analysis and repeat primed PCR [124], although South-
ern blotting is necessary for accurate estimation of the repeat
size. Genetic screening in FALS cases is routinely undertaken
following counseling of the patients and consent. Given that
C9orf72 expansions are found in up to 7–19 % of patients
with ALS with apparently sporadic disease in different popu-
lations, the question arises as to whether all ALS cases should
be offered screening for changes in this gene. Consensus has
not yet been reached in relation to this issue, although genetic
counseling considerations for individuals at risk for a C9orf72
repeat expansion have been reviewed [125, 126]. Psycholog-
ical, social and ethical implications of genetic testing in ALS
are still relatively unexplored.
Conclusion
Study ofC9orf72 disease is proceeding at a rapid pace and has
delivered perhaps the most significant increase in understand-
ing of ALS pathogenesis in the last 20 years. The most recent
advances summarized in this review concern the changes in
our understanding of potential RNA- and protein-mediated
mechanisms of pathogenesis. An interesting convergence
has recently occurred where, through different mechanisms,
it appears that RNA foci and DPRs may affect the same tar-
gets: pre-mRNA splicing mediated by RNA recognition motif
(RRM)-containing, SR-containing proteins and the normal
function of the nucleolus in ribosome production. The poten-
tial involvement of the ribosome is interesting and studies of
the Btranslatome^ are awaited.
The recent flurry of evidence for toxicity mediated via
DPRs is exciting and is reminiscent of the polyQ proteins
produced in other repeat-associated neuromuscular diseases.
However, other genetic variants of ALS/FTD, most promi-
nently patients with mutations of TARDBP, do not have a
means of producing a protein-repeat sequence, despite clinical
and pathological similarities to the C9orf72 disease. What is
shared is the potential for RNA-mediated toxicity as TDP-43
is a key RNA processing protein [15], and a number of lines of
evidence have pointed to its RNA processing function in the
pathogenesis of neuronal injury [127, 128]. As the lessons
learned from SOD1-related ALS have shown over the last 2
decades [129], it is likely that C9orf72-mediated ALS will
prove to be multifaceted and complex; this is consistent with
the wide variability of the clinical phenotype and disease
course in this genetic subgroup of patients.
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